Can a diabetes drug shield the heart during a heart attack procedure?
NCT ID NCT07749014
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This trial tests whether giving empagliflozin before or after a procedure to open a blocked heart artery (primary PCI) reduces heart muscle injury during a heart attack. Adults aged 18-75 of South Asian origin having their first heart attack will be randomly assigned to receive empagliflozin before the procedure, after it, or a placebo. Researchers will measure heart damage via blood tests and heart scans over 90 days to see if the timing of the drug matters.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- empagliflozin (an SGLT2 inhibitor drug, also known as Jardiance)
- What this could lead to
- If timing empagliflozin before the artery-opening procedure reduces heart muscle damage, it could become a standard part of heart attack care, potentially improving recovery and reducing long-term heart failure risk.
- What could go wrong
- This is a phase 2 trial, so results are preliminary. The benefit may be small or not appear, and empagliflozin can have side effects like urinary infections or dehydration. Findings in South Asian patients may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION (AMI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rehman Medical Institute
Peshawar, Khyber Pakhtun Khwa, 25000, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Software-Guided heart procedures: a new standard for coronary care?
- Heart patients may stay active longer with coach calls and group support
- Sitting less could be a lifeline for frail hearts – a new trial tests a simple program
- Can balloon timing make or break heart artery success?
- Can a temporary heart pump save more lives in cardiogenic shock?
- Can we predict which heart aneurysms will grow?